14th International Rotavirus Symposium

Opening Session

Opening Address – Dr. Rizka Andalucia, Ministry of Health, Indonesia

Overview of Rotavirus and Rotavirus vaccines – Duncan Steele, Bill & Melinda Gates Foundation

Tribute to Prof Yati Soenarto

Session I: Rotavirus Disease and Control in Indonesia

The burden of rotavirus disease in Indonesia- Hera Nirwati, Universitas Gadjah Mada

A cost-effectiveness analysis of rotavirus vaccine for Indonesia- Jarir At Thobari, Universitas Gadjah Mada

Model based estimation of the impact on rotavirus disease of the RV3-BB vaccine administered in a neonatal or infant schedule in Indonesia
– Vicka Oktaria, Universitas Gadjah Mada

Development of the neonatal rotavirus vaccine at PT Biofarma – Adriansjah Azhari, Biofarma

Plans for implementation of Rotavirus Vaccine in Indonesia – Prima Yosephine, Ministry of Health, Indonesia

Session II: Global Rotavirus Disease burden and Impact of Rotavirus vaccines

Challenges to childhood immunization during the COVID-19 pandemic – Anuradha Gupta, Sabin Vaccine Institute

Rotavirus hospitalizations among children under 5 years of age, 2017-2021: Findings from the Global Rotavirus Surveillance Network- Heidi Soeters, World Health Organization

Etiology of hospitalized diarrhea in children in low- and middle-income countries: Results from the Global Pediatric Diarrhea Surveillance Network, 2017-2020 – James Platts-Mills, University of Virginia

Changing landscape of moderate-to-severe diarrhea among children in three sub-Saharan African countries following rotavirus vaccine introduction:  The Vaccine Impact on Diarrhea in Africa (VIDA) Study – Dilruba Nasrin, University of Maryland

Global impact of rotavirus vaccination in the pre-COVID-19 era: A modelling analysis – Sarwat Mahmud, London School of Hygiene & Tropical Medicine

Impact of rotavirus vaccination in 112 countries from 2006 to 2034 – Aniruddha Deshpande, Emory University

Session III:   Insights on rotavirus disease burden and rotavirus vaccine introduction in the Region

Rotavirus epidemiology and the potential impact of vaccination in Dhaka, Bangladesh – Ernest O Asare, Yale University

A decade long study on Group A rotavirus infection and genotype diversity among children with acute gastroenteritis in Kolkata, East India (2012-2022) – Shanta Dutta, ICMR-National Institute of Cholera and Enteric Diseases

Etiology of gastroenteritis pathogens among hospitalized children under 5 years of age in the Philippines, 2017-2019 – CEI Lazaro-Oasin, Department of Health-Research Institute for Tropical Medicine

Early impact on rotavirus disease by the monovalent Rotavac vaccine in India – Venkata Raghava, Christian Medical College Vellore

Post-introduction Evaluation in India – Veena Dhawan, Ministry of Health and Family Welfare, India

Session IV:    Roger Glass Keynote Lecture

Roger Glass Lecture – From discovery to implementation: the journey of RV3BB to target disease prevention from birth – Julie Bines, Murdoch Childrens Research Institute

Session V:     Policy, Access and Implementation of oral rotavirus vaccines

GAVI rotavirus vaccines support: supply challenges, implementation challenges, and optimization opportunities for countries – Veronica Denti, Gavi, the Vaccine Alliance

Rotavirus vaccine product switch: Experience under the Universal Immunization Programme in India – Seema Singh Koshal, John Snow Inc.

Impact and cost-effectiveness of rotavirus vaccination in Non-Gavi Low- and Middle-Income Countries – Frederic Debellut, PATH

Rotavirus vaccine product switch in Ghana: An assessment of service delivery costs, program switch costs and cost-effectiveness – Richmond Owusu, School of Public Health, University of Ghana

Panel Discussion: Increasing rotavirus vaccine coverage-opportunities and challenges – Deborah Atherly, PATH, Zulkifli Ismail, KPJ Healthcare University College, Malaysia, Tony Nelson, Chinese University of Hong Kong Shenzhen

Session VI:  Real world impact of Rotavirus Vaccines

Impact assessment of rotavirus vaccine introduction in Pakistan’s routine immunization program – Atif Riaz, Aga Khan University

Impact and effectiveness of Rotavin-M1 under conditions of routine use in two provinces in Vietnam, 2016-2021- Nguyen Van Trang, National Institute of Hygiene and Epidemiology

Impact of the introduction of Rotarix (2016-2018) and Rotavac (since 2018) in the West Bank, Palestinian Territories – Wolfgang Rennert, Caritas Baby Hospital

Session VII:   New insights into rotavirus immune responses and virology

Induction of systemic and mucosal neutralizing antibodies to norovirus and rotavirus after oral administration of a live recombinant rotavirus to suckling mice – Harry Greenberg, Stanford University

Maternal breast milk secretor phenotype does not affect infant susceptibility to rotavirus diarrhea – Benjamin Lee, University of Vermont College of Medicine

Elevated levels of pre-existing growth factors and cytokines are associated with rotavirus vaccine take in Malawian infants – Khuzwayo Jere, Malawi-Liverpool Wellcome Trust Clinical Research Programme

RotaTeq and Rotarix rotavirus vaccines immunogenicity in malnourished infants in Bangladesh and Bolivia – Daniel Velasquez-Portocarrero, Centers for Disease Control and Prevention, US

Session VIII:    Advances in our understanding of rotavirus pathophysiology

Understanding the interplay between host, microbiome and an orally delivered probiotic rotavirus vaccine platform – Gregg Dean, Colorado State University

Harnessing the potential of the gut microbiome to improve oral rotavirus vaccine responses – Sashi Ramani, Baylor College of Medicine

Profiles and influence of maternal and infant histo-blood group antigens on oral rotavirus vaccine (Rotarix) immunogenicity in Zambia – Adriace Chauwa, Centre For Infectious Disease Research In Zambia

Rotavirus NSP4 mediated increase in intracellular calcium results in increased levels of the pro-inflammatory eicosanoid, prostaglandin E2, during infection – Hester O’Neill, University of the Free State

Host long non-coding RNAs: Key modulators in rotavirus infection dynamics – Shreya Banerjee, ICMR-National Institute of Cholera and Enteric Diseases

The role of aryl hydrocarbon receptor (AhR) signaling in determining the susceptibility to rotavirus infection – Nurul Iffat Wirusanti, Department of Global Health, Amsterdam UMC

Session IX:   Ruth Bishop Keynote Lecture

Ruth Bishop Lecture – New Insights into Rotavirus Pathogenesis and Vaccines – Mary Estes, Baylor College of Medicine

Session X:   Advances in Understanding of Rotavirus Disease

Rotavirus in the time of SARS-CoV-2: The South African story, 2018-2022 – Nicola Page, National Institute for Communicable Diseases

Association between maternal breast milk microbiota composition and rotavirus vaccine responses in Africa, Asian and European infants – Khuzwayo Jere, Malawi-Liverpool Wellcome Trust

Immunogenicity of a third scheduled dose of Rotarix in Australian indigenous children: A Phase IV, double blind, randomized, placebo-controlled clinical trial – Bianca Middleton, University of Sydney

Comparison of rotavirus and norovirus post-rotavirus vaccine introduction in 3 sub-Saharan African countries, 2015-2018 – Richard Omore, Kenya Medical Research Institute

Interchangeable vaccine dosage algorithm for available rotavirus vaccine products in India: A pragmatic alternative to single vaccine product regimens – Suman Kanungo, ICMR-National Institute of Cholera and Enteric Diseases

Natural Killer T-cells are altered in Malawian infants immunized with the neonatal RV3-BB rotavirus vaccine – Prisca Benedicto-Matambo, Kamuzu University

Cohort study of the characteristics of neonatal rotavirus infection and the establishment of a transmission kinetic model in China – Si-Jie Wang, Fudan University Shanghai Medical College

Assessment of nutritional status and its association with clinical severity among Under 5 children admitted with diarrhea in India – Namrata Kharat, Christian Medical College Vellore

Session XI:   Rotavirus Molecular Epidemiology pre- and post-vaccine introduction

Rotavirus genotype distribution after the introduction of rotavirus vaccines in India, 2016-2020 – Tintu Vargese, Christian Medical College Vellore

Genotypic surveillance and epidemiologic trends of rotavirus infection among children with gastroenteritis in Bangladesh, 2014-2021 – Shuvra Kanti Dey, Jahangirnagar University, Dhaka

Genomic constellation of human G8 strains in Brazil over a 13-year period: Detection of the novel bovine-like G8P[8] DS-1-like virus – Adriana Luchs, Adolfo Lutz Institute

Epidemiology of enteric viruses in children Under 5-years before and after rotavirus vaccine introduction in Maniçha District, Mozambique, 2007-2019 – Percina Chirinda, Manhiça Health Research Center

Characterizing the diversity of unusual rotavirus strains in Australian children and adults –  Celeste Donato, Murdoch Childrens Research Institute

The molecular epidemiology of human rotavirus and strain diversity in Kenya pre- and post- rotavirus vaccine introduction: A review – Grace Irimu, University of Nairobi, Kenya

Session XII:   Progress towards next generation rotavirus vaccines

Interim results from a phased 3 trial of a parenteral rotavirus vaccine candidate in healthy infants in Africa – Tushar Tewari, PATH

Progress towards clinical trial of inactivated rotavirus vaccine – Baoming Jiang, Centers for Disease Control and Prevention, US

Potential impact and cost-effectiveness of injectable, next generation rotavirus vaccines in 137 LMICs: A modelling study – Frederic Debellut, PATH

Session XIII:  Closing Ceremony

Best Poster Award Winners:
·        Allison Vilander
·        Anupama Machathi
·        Lerato Kgosana
·        Ly Thi Khanh Le
·        Pempa Pempa
·        Warda Haque

Closing address – Cherry Kang, Christian Medical College Vellore